FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer By Ogkologos - February 6, 2025 450 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eXALT3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR What’s happened to cancer services during the COVID-19 pandemic? September 11, 2020 How To Respond When Your Parents Are Critical Of Your Parenting... November 14, 2019 A Poet’s Autobiography of Cancer May 31, 2023 FDA Approves Nivolumab for Resected Oesophageal or Gastro-oesophageal Junction Cancer May 25, 2021 Load more HOT NEWS FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head... First Study to Demonstrate that PD1 Immune Checkpoint Blockade May Yield... 40 K9 Officers Line Up Outside Terminally Ill Girl’s House For... Opinion: What should the cancer agenda look like for the new...
